| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $102.0M | -0.7% | +3.8% |
| SG&A Expense | $35.5M | +10.0% | +42.2% |
| Operating Income | -$137.4M | -1.8% | -11.6% |
| Net Income | -$126.9M | -2.2% | -18.4% |
| EPS (Basic) | -$0.74 | -2.8% | -17.5% |
| EPS (Diluted) | -$0.74 | -2.8% | -17.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $91.0M | -35.6% | +0.4% |
| Short-term Investments | $757.2M | -0.1% | +1.5% |
| Current Assets | $882.6M | -5.6% | +1.6% |
| Total Assets | $1.06B | -9.5% | -27.4% |
| Current Liabilities | $90.1M | -1.0% | +3.5% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$314.1M | — | — |
| Capital Expenditures | $8.0M | — | — |
| Investing Cash Flow | $234.5M | — | — |
| Financing Cash Flow | -$2.9M | — | — |
| Free Cash Flow | -$322.0M | — | — |
| $129.4M |
| -7.0% |
| -4.5% |
| Stockholders' Equity | $926.2M | -9.8% | -29.8% |